A New Path Forward for Depression & OCD

Transcranial Magnetic Stimulation (TMS) is a non-invasive treatment that uses gentle magnetic pulses to activate & strengthen areas of the brain involved in mood regulation.

There’s no medication, no anesthesia, and no downtime—most people return to normal activities immediately after their session .

It’s an FDA-cleared, evidence-based option for people who haven’t found relief from antidepressants.

Find relief with FDA-cleared NeuroStar® TMS — a safe, medication-free neurotherapy used by thousands to overcome treatment-resistant depression & OCD.


X

Get Started

Is NeuroStar® TMS right for you?

Therapy hasn’t provided significant relief

You want a non-invasive, medication-free treatment option

You may be a good candidate for TMS if:

You are diagnosed with MDD or OCD

Medication trials were ineffective or produced unwanted side effects

TMS is FDA-cleared for adults & adolescents 15+ and may be covered by insurance.

What to expect?

Intake & Mapping

Daily Treatment Sessions

Monitoring & Support


NeuroStar® Treatment Results & Outcomes

0
Nationwide Treatments
The NeuroStar® treatment device has administered more than eight million treatment sessions across the United States, making it one of the most trusted & widely used TMS systems available.
0%
Meaningful Improvement
A real-world study reported 83% of clients receiving NeuroStar® treatment experienced significant improvement in their depressive symptoms after completing a full course of treatment.
0%
Complete Remission
The same real-world study reported 62% of clients receiving NeuroStar® treatment achieve full or mostly full clinical response. This means those clients likely wouldn't be diagnosed with MDD if they were being evaluated by a doctor post-treatment.

Insurance, Coverage, and Cost

We’re in-network with most major insurance providers.

We work with these insurance providers & more to help make NeuroStar® TMS accessible and affordable.

If eligible for treatment, our team verifies your coverage and manages authorization on your behalf.

FAQ

Meet your TMS Team

  • Hunter M

    VP OF BUSINESS OPERATIONS

    TMS PROGRAM DIRECTOR

  • Matthew P

    PMHNP

    PROGRAM CLINICAL DIRECTOR

  • Dr. Louis P

    Psychiatrist

    PROGRAM SUPERVISING PHYSICIAN

  • Megan C

    BILLING OPERATIONS MANAGER

    TMS BILLING SUPERVISOR

  • Brittany Z

    MEDICAL BILLING SPECIALIST

    TMS BILLING COORDINATOR

  • Francis T

    ADMINISTRATIVE ASSISTANT

    TMS CARE COORDINATOR

  • Kristy M

    PRACTICE MANAGER

    TMS Tech

  • Bridgett C

    PBH MOP

    TMS TECH

  • Douglas G

    PBH TSF

    TMS TECH

  • Haley O

    OUTPATIENT THERAPIST

    TMS TECH

  • Haley L

    MEDICAL COORDINATOR

    TMS TECH


Indications & Clinical References

[1] The NeuroStar Advanced Therapy System is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode.

The NeuroStar Advanced Therapy System is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).

[2] NeuroStar Advanced Therapy is indicated as an adjunct for the treatment of Major Depressive Disorder (MDD) in adolescent patients (15-21).

Important Safety Information  

NeuroStar Advanced Therapy is only available by prescription. A doctor can help decide if NeuroStar Advanced Therapy is right for you. Patients’ results may vary.  

The most common side effect is pain or discomfort at or near the treatment site. These events are transient; they occur during the TMS treatment course and do not occur for most patients after the first week of treatment. There is a rare risk of seizure associated with the use of TMS therapy (<0.1% per patient).  

Visit neurostar.com for full safety and prescribing information. 

[3] Outcomes Registry data was published by Sackeim HA, et al. J Affective Disorders, 2020, 277(12):65-74. The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score <=3 and “complete remission” was defined as a CGI-S score <=2 at the end of treatment.

[4] NeuroStar Advanced Therapy is only available by prescription. A doctor can help decide if NeuroStar Advanced Therapy is right for you. Patients’ results may vary. Visit neurostar.com for full safety and prescribing information.